221 related articles for article (PubMed ID: 29229583)
21. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.
Knipper S; Preisser F; Mazzone E; Mistretta FA; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2019 Jun; 17(3):231-237.e2. PubMed ID: 31080021
[TBL] [Abstract][Full Text] [Related]
22. PIN-like (Ductal) Adenocarcinoma of the Prostate.
Paulk A; Giannico G; Epstein JI
Am J Surg Pathol; 2018 Dec; 42(12):1693-1700. PubMed ID: 30138215
[TBL] [Abstract][Full Text] [Related]
23. Improved differentiation between ductal and acinar prostate cancer using three-dimensional histology and biomarkers.
Tarján M; Chen HH; Tot T; Wu W; Lenngren A; Dean PB; Tabár L
Scand J Urol Nephrol; 2012 Aug; 46(4):258-66. PubMed ID: 22519924
[TBL] [Abstract][Full Text] [Related]
24. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Schweizer MT; Cheng HH; Tretiakova MS; Vakar-Lopez F; Klemfuss N; Konnick EQ; Mostaghel EA; Nelson PS; Yu EY; Montgomery B; True LD; Pritchard CC
Oncotarget; 2016 Dec; 7(50):82504-82510. PubMed ID: 27756888
[TBL] [Abstract][Full Text] [Related]
25. Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63.
Torabi-Nezhad S; Malekmakan L; Mashayekhi M; Daneshian A
Prostate; 2016 Mar; 76(4):394-401. PubMed ID: 26643011
[TBL] [Abstract][Full Text] [Related]
26. Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma.
Iakymenko OA; Lugo I; Kwon D; Zhao W; Hayee A; Punnen S; Parekh DJ; Pollack A; Ritch CR; Gonzalgo ML; Stoyanova R; Jorda M; Kryvenko ON
Urology; 2020 Mar; 137():108-114. PubMed ID: 31711982
[TBL] [Abstract][Full Text] [Related]
27. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Jiao Y; Yonescu R; Offerhaus GJ; Klimstra DS; Maitra A; Eshleman JR; Herman JG; Poh W; Pelosof L; Wolfgang CL; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N; Wood LD
J Pathol; 2014 Mar; 232(4):428-35. PubMed ID: 24293293
[TBL] [Abstract][Full Text] [Related]
28. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
29. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
[TBL] [Abstract][Full Text] [Related]
30. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
Shi C; Hong SM; Lim P; Kamiyama H; Khan M; Anders RA; Goggins M; Hruban RH; Eshleman JR
Mol Cancer Res; 2009 Feb; 7(2):230-6. PubMed ID: 19208745
[TBL] [Abstract][Full Text] [Related]
31. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
[TBL] [Abstract][Full Text] [Related]
32. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
Lindberg J; Klevebring D; Liu W; Neiman M; Xu J; Wiklund P; Wiklund F; Mills IG; Egevad L; Grönberg H
Eur Urol; 2013 Feb; 63(2):347-53. PubMed ID: 22502944
[TBL] [Abstract][Full Text] [Related]
33. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
Samaratunga H; Duffy D; Yaxley J; Delahunt B
Hum Pathol; 2010 Feb; 41(2):281-5. PubMed ID: 20004936
[TBL] [Abstract][Full Text] [Related]
34. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
35. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
37. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract][Full Text] [Related]
38. Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.
Rao SR; Protheroe A; Cerundolo L; Maldonado-Perez D; Browning L; Lamb AD; Bryant RJ; Mills IG; Woodcock DJ; Hamdy FC; Tomlinson IPM; Verrill C
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628903
[TBL] [Abstract][Full Text] [Related]
39. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
40. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
